A mutlicentre, double blind randomised study to compare the safety, tolerability and efficacy of quetiapine and risperidone in the treatment of schizophrenia in patients previously treated with antipsychotic medication with inadequate symptom control.IRIS - Improved response in Schizophrenia.
Study identifier:BU-5077-0015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A mutlicentre, double blind randomised study to compare the safety, tolerability and efficacy of quetiapine and risperidone in the treatment of schizophrenia in patients previously treated with antipsychotic medication with inadequate symptom control.IRIS - Improved response in Schizophrenia.
Medical condition
schizophrenia
Phase
Phase 4
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Dec 2002
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
-
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
